
==== Front
Yale J Biol MedYale J Biol MedThe Yale Journal of Biology and Medicine0044-00861551-4056Yale Journal of Biology and Medicine Cancer MechanismsCancer issueMultiple Endocrine Neoplasia Type 1 (MEN1) as a Cancer Predisposition Syndrome: Clues into the Mechanisms of MEN1-related Carcinogenesis Busygina Valeria ab*Bale Allen E. b
a Department of Biophysics and Biochemistry, Yale University School of Medicine, New Haven Connecticut
b Department of Genetics, Yale University School of Medicine, New Haven, Connecticut* To whom all correspondence should be addressed: Valeria Busygina, Ph.D., Department of Biophysics and Biochemistry, Yale University School of Medicine, 333 Cedar Street, SHM C-130, New Haven, CT 06520. Tel: 203-785-4569; E-mail: valeriya. busygina@yale.edu.10 2007 12 2006 79 3-4 105 114 Copyright ©2006, Yale Journal of Biology and Medicine2006Yale Journal of Biology and MedicineThis is an open access article distributed under the terms of the Creative Commons CC BY-NC license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use the material for commercial purposes.
==== Body
Cancer is a major public health problem in the United States and around the world with millions of new cases diagnosed each year. While most of the cancers occur sporadically, a number of familial cancer predisposition syndromes have been identified in recent years. Cancer susceptibility syndromes are responsible for an estimated 5 to 10 percent of all cancer cases. Genes responsible for hereditary cancers are often also mutated in sporadic cancers. Studies of cellular functions of cancer susceptibility genes have made an invaluable contribution to our understanding of tumorigenesis.

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant cancer predisposition syndrome, the gene for which encodes a nuclear protein: menin. The biochemical function of this protein is largely unknown, but several studies have shown a role in transcriptional modulation through interaction with histone deacetylases and histone methyltransferases. Tumors in MEN1 arise through a two-hit mechanism, suggesting that menin either negatively regulates cell growth or participates in maintenance of genomic integrity.

In this work, we provide a general overview of the hereditary cancer syndromes with both dominant and recessive mode of inheritance. We then discuss recent advances in understanding the biological role of MEN1 gene and the mechanisms by which inactivation of MEN1 may lead to neoplastic transformation.

Hereditary cancer predisposition syndromes
Despite the complexity of cancer as a disease, there are some common features shared by all cancer cells that distinguish them from their normal counterparts. They are immortal and have a high proliferative potential. They no longer require external growth signals to activate the proliferation program and are insensitive to growth inhibitory signals. They have developed mechanisms for evading senescence and programmed cell death, or apoptosis. In order to ensure tumor growth, the cells of solid tumors must promote the formation of new blood vessels for oxygen and nutrient supply. And, finally, malignant cells fail to exhibit normal cell-cell interactions, which results in their ability to invade and to metastasize and grow in an abnormal cellular environment [1]. The acquisition of these qualities is not a single event but rather the result of an accumulation of multiple genetic alterations leading to escape from normal control of growth regulation and differentiation [2].

Genes with very diverse cellular functions have been implicated in carcinogenesis. This includes genes involved in intracellular signaling cascades, cell cycle control, cell differentiation, apoptosis, protein synthesis and degradation, organization of cytoskeleton, cell migration, cell-cell interaction, regulation of transcription, chromatin remodeling, and DNA damage sensing and repair [3-5]. Understanding how the disruption of these cellular processes leads to tumor formation is the key to rational development of effective cancer therapies.

Because the development of cancer is a multi-step process, it may take years between the occurrence of the first genetic lesion and the actual formation of malignant neoplasm. Thus, the incidence of cancer increases with age. In rare cases, however, individuals inherit a mutant allele of a cancer predisposition gene, which increases the mutation rate and promotes the development of cancer. Thus, individuals with cancer predisposition syndromes have both a greater risk of developing cancer and an average earlier age of onset compared to the general population.

In 1971, Knudson proposed his famous “two-hit” hypothesis [6]. By observing patients with familial and sporadic retinoblastoma, he suggested that individuals with familial cases inherited the first genetic lesion, or “hit,” and that they only needed to acquire one more hit to develop cancer. These patients developed retinoblastoma at an earlier age than individuals with sporadic tumors who needed to acquire two somatic hits in the same cell. This hypothesis was confirmed with the discovery of the retinoblastoma (RB1) gene in 1986 [7]. Indeed, individuals with familial retinoblastoma inherited a germline mutation in one allele of the RB1 gene with the remaining wild type allele being lost in tumors, often through a process involving large deletions with loss of heterozygosity (LOH) for surrounding polymorphic loci [7].

Since the discovery of RB1, multiple tumor-predisposition genes have been identified by the study of familial cancer syndromes. It is estimated that 5 to 10 percent of all cancers develop in individuals who have inherited a mutation conferring cancer susceptibility [8]. Analysis of the genes responsible for hereditary cancer predisposition and the pathways in which they act has been critically important in providing insight into cancer formation, because the same genes that are affected in cancer-predisposition syndromes are often responsible for the majority of somatic cancer cases as well. For example, germline mutations in the APC gene account for less than one percent of all colorectal cancers, but APC is also inactivated in nearly all sporadic colon cancers [2].

More than 50 cancer predisposition syndromes have been identified to date [8,9] with both dominant and recessive modes of inheritance (Table 1). Activating mutations in oncogenes occur only in a few cases, such as RET in multiple endocrine neoplasia type 2 (MEN2) [10] and MET in familial papillary renal carcinoma [11]. Activated oncogenes function dominantly in the cell, and mutation of the second allele is not required. Most of the dominantly inherited cancer syndromes, however, have an inactivating mutation in a tumor suppressor, and disease formation follows the two-hit rule. The first hit is a germline mutation that exists in every cell of the body. Somatic inactivation of the second allele of the same locus in certain tissues may initiate neoplastic transformation. Thus, cancer predisposition syndromes often have dominant mode of inheritance at the level of the organism, but at the cellular level they are recessive because inactivation of both copies of the gene is required for cancer formation.

Genes whose inactivation leads to tumorigenesis are divided into two distinct groups: gatekeepers and caretakers. Gatekeepers are usually “classical” tumor suppressors that directly regulate cell growth, differentiation, and death in certain tissues. Dysregulation of a gatekeeper is necessary to initiate neoplastic transformation. Examples of gatekeepers include APC for colon epithelia, RB1 for retinal epithelia, NF1 for Schwann cells, and VHL for kidney cells [2,12]. Inactivation of both homologs of these genes is found both in hereditary forms of cancer and in the majority of sporadic cancers of the same type. In contrast to gatekeepers, caretaker genes do not directly regulate cell growth. Caretaker genes are involved in DNA repair and maintenance of genomic integrity. Inactivation of a caretaker does not directly promote tumor formation but facilitates the development of mutations in gatekeeper genes and other cancer-related genes. Caretakers, like gatekeepers, may be tissue-specific, but mutation in a caretaker is neither necessary nor sufficient for the development of cancer. Mutations in some caretaker genes cause human cancer by the two-hit mechanism. For example, patients with familial breast cancer syndromes inherit one mutant copy of BRCA1 or 2, and LOH for the second allele is found in tumors of breast and ovary [13-16]. Similarly, in hereditary non-polyposis colorectal cancer (HNPCC), one mutant copy of mismatch repair genes such as MLH1, MSH2, or MSH6 is inherited, and the wild type allele is lost in tumors of the colon [17]. However, unlike gatekeepers, mutations in caretakers are uncommon in sporadic tumors of the types seen in the hereditary disease [18].

A number of human cancer predisposition syndromes have a recessive mode of inheritance (Table 1). These syndromes are also called genetic instability syndromes, because one of the hallmarks of these diseases is chromosomal instability and hypersensitivity to various DNA damaging insults. The genes mutated in these diseases, such as ATM, Fanconi anemia complementation group, NBS1, Xeroderma pigmentosum-associated genes (XPA, XPC, etc.), BLM, and RECQL4, function in DNA damage sensing or repair [4,8,9] and can be classified as caretakers by analogy with the BRCA and HNPCC genes.

 Since the identification of the first cancer predisposition gene (RB1) in 1986, tremendous advances have been made in understanding the function of multiple genes implicated in both sporadic and hereditary cancers. However, the mechanism of action of many more recently identified genes is not well understood. Further studies are necessary to provide new insights into human neoplasia and improve the diagnosis and treatment of both sporadic and hereditary cancers.

Multiple endocrine neoplasia type 1 (MEN1)
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant cancer predisposition syndrome characterized by parathyroid, pancreatic islet, and pituitary tumors as well as other neoplasms such as gastrinomas, carcinoids, lipomas, angiofibromas, angiomyolipomas and thyroid tumors [19]. Clinical manifestations depend on the affected organ. Most MEN1-associated tumors are not metastatic but create clinical effects by overproduction of hormones such as insulin, glucagon, prolactin, parathyroid hormone, gastrin, growth hormone, or adrenocorticotropic hormone [19,20]. The most common manifestation of the disease is parathyroid adenoma, with penetrance reaching almost 100 percent by the age of 50 [19]. Major causes of morbidity and mortality in MEN1 are gastrinomas and foregut carcinoids, which are often highly metastatic [19]. The estimated prevalence of MEN1 is one in 30,000 [21].

MEN1 was localized to chromosome 11q13 by linkage analysis, and the gene was later identified by positional cloning [23,24]. Tumors in MEN1 arise through the two-hit mechanism with germline mutation in one copy of the gene and somatic loss of the normal allele [22]. Germline mutations in MEN1 are mainly nonsense or frameshift and are presumed to cause inactivation of the gene. The transcript of the MEN1 gene contains an open reading frame predicted to encode 610 amino acid proteins. Analysis of the sequence of the protein menin showed two nuclear localization signals near the carboxyl terminus but has not provided any other clues to its function. Immunocytochemical studies of interphase somatic cells show that the protein is located in the nucleus [25]. Studies in human and mouse show that MEN1 is expressed widely in adult and fetal tissues with high levels in the CNS, lung, liver, kidney, testis, and fetal thymus [23,26-28].

Among the earliest studies of menin function was a yeast two-hybrid analysis showing interaction between menin and JunD, a component of the AP-1 transcription factor [29]. Studies in mammalian tissue culture systems showed that the N-terminal half of menin could inhibit JunD-mediated transcription. Menin did not bind to other AP-1 components such as c-Jun, JunB, or four members of the Fos family. Further investigation of menin’s involvement in JNK and other MAP kinase signaling cascades revealed that overexpression of MEN1 in some cell lines inhibited ERK-mediated phosphorylation of JunD and Elk1 and JNK-dependent phosphorylation of JunD and c-Jun [30]. In addition, overexpression of menin in CHO-IR cells suppressed insulin-induced activation of AP-1 and transcriptional induction of c-Fos [31]. Similarly, menin was shown to bind to and inhibit transcriptional activation by several members of the NF-κB family of transcription factors [32]. Binding of menin to SMAD3 appears to enhance transcriptional activation function, and loss of menin blocks TGF beta signaling [33]. The homeobox-containing protein Pem [34] has also been shown to bind menin in biochemical assays. These data suggest that menin may act as a transcriptional regulator. Our investigations of the Drosophila MEN1 homolog showed in vivo interaction of MEN1 with JNK signaling pathway components. We also found that when tethered to DNA, Drosophila menin acts as a transcriptional repressor. Menin does not have any recognizable DNA binding motifs, and data are conflicting as to whether menin can directly bind DNA and whether it binds in a sequence-specific manner [35,36].

Multiple lines of evidence exist to support menin’s involvement in transcriptional control and chromatin modification. Human menin was found to bind and control the activity of multiple transcription factors. Menin interacts with mSin3a, a component of the Sin3/Rpd3 HDAC complex [37], and with a histone methyltransferase complex containing the trithorax family proteins MLL2 and Ash2L [38-41]. In addition, menin was found to bind to the promoter regions of several homeobox genes and to regulate their expression [38,39]. Genome-wide analysis of genomic binding sites showed menin’s localization to the promoters of multiple genes [42,43]. Recently, two other transcription targets of menin were identified. Cyclin-dependent kinase inhibitors p27kip1 and p18Ink4c are downregulated in menin-deficient cells, which also exhibited increased proliferation [40]. Thus, menin may control cell proliferation through regulating transcription of genes involved in cell cycle control.

That tumors in MEN1 arise through two-hit mechanism suggests that menin may act in the regulation of cell growth or in the maintenance of genomic integrity, as discussed above. Several lines of evidence suggest that menin might participate in DNA damage sensing or repair. Peripheral blood lymphocytes from MEN1 patients have an elevated frequency of chromosomal abnormalities after exposure to the cross-linking agent diepoxybutane (DEB) [44]. Menin-deficient mouse embryonic fibroblasts (MEFs) are hypersensitive to DEB [45]. Menin interacts with FANCD2, a gene that underlies the genetic instability syndrome Fanconi anemia. Moreover, this interaction is strengthened after the exposure of cells to γ-irradiation [45]. In addition, menin was shown to interact with replication protein A (RPA) [46], a protein that binds single strand DNA and is important for several DNA repair pathways [47]. Studies from our laboratory show a role for the Drosophila homolog of MEN1 in maintenance of genomic integrity. We found that inactivation of Men1 in Drosophila results in flies that are sensitive to certain types of DNA damage, in particular to ionizing radiation and DNA cross-linking agents. In addition, Men1-deficient flies have an elevated mutation rate both at baseline and after treatment with ionizing radiation and nitrogen mustard (a cross-linking agent) [48]. Menin-deficient tissues from both Drosophila and mammals fail to undergo S-phase arrest in response to DNA damage by ionizing radiation [49]. These data suggest that tumor pathogenesis in the human disease may relate to genomic instability.

 Studies also support a direct role for MEN1 in the control of cell growth and differentiation. Overexpression of menin represses the proliferation and tumorigenesis of Ras-transformed NIH3T3 cells and insulinoma cells [50]. Data are conflicting as to whether menin-deficient mouse cells have increased proliferative capacity. One study found no cell-autonomous proliferative defects in Men1-/- embryonic stem (ES) cells or embryonic fibroblasts (MEF) [51]. However, another study showed that Men1-/- MEFs have increased proliferative capacity, and reintroduction of wild type menin suppresses their growth, possibly through an interaction with activator of S-phase kinase (ASK), a component of the Cdc7/ASK kinase complex [52]. Some phenotypes seen in mouse models of MEN1 suggest a direct role in growth control. For example, tissue-specific gene inactivation in pancreatic islet cells of the mouse leads to widespread hyperplasia, consistent with a similar role for the gene postnatally [53].

A mouse model with targeted disruption of the Men1 gene showed that menin has an essential role in development [54]. The phenotype of heterozygotes was very similar to the human MEN1 phenotype with tumors of the parathyroid, pituitary, pancreatic islets, thyroid, and adrenal cortex. Homozygous mice died in utero. They appeared normal at E9.5 but by E11.5-12.5 were developmentally delayed and smaller than normal littermates. Virtually all fetuses were resorbed by E14.5. Morphological defects included an open neural tube, hypoplastic myocardium, and an extremely malformed liver with abnormal organization of the epithelial and hematopoietic compartments and increased apoptosis [51]. Conditional knockout of Men1 in mouse pituitary and pancreatic islets showed that both these organs were able to develop normally even if Men1 was deleted in early embryogenesis. Pancreatic islets developed β-cell hyperplasia and later, in six- to 12-month-old mice, pancreatic islet adenomas. Insulinomas and prolactinomas developed in some animals starting at nine months. The late tumorigenesis in these mice suggests that additional somatic events are necessary to promote cancer formation [53,55].

Two studies suggested a function of menin related to telomeres. Investigations in our laboratory [56] showed that menin localizes to telomeres during meiotic prophase in mouse spermatocytes. Menin foci were seen only at this location and not in other regions of meiotic cells. The foci were apparent as soon as axial elements began to form, and signals increased in intensity throughout prophase. However, menin did not co-localize with telomeric proteins, such as TRF2, in somatic cells at any stage of the cell cycle. Furthermore, telomeres of MEN1-related tumors were no different in length than telomeres of histologically similar sporadic tumors arising without MEN1 mutations. Overexpression of menin did not influence telomerase activity as assessed by TRAP assays. Another study, which systematically examined the effects of tumor suppressor genes on telomere maintenance, suggested that loss of menin function might stimulate telomerase (hTERT) expression [57] and that menin might be involved in tumorigenesis through this mechanism.

Menin has also been found to associate with several cytoskeleton components. Menin’s interaction with the intermediate filament proteins GFAP and vimentin was suggested to control its nuclear import [58]. Another cytoskeletal interactor of menin is nonmuscle myosin II-A heavy chain protein, which was found to co-localize with menin at the cleavage furrow during cytokinesis [59].

Conclusions and outlook
In the 10 years since the MEN1 gene was first cloned, a wealth of information concerning its possible function in tumorigenesis has been obtained. The accumulated genetic and biochemical data show that menin has multiple binding partners in a cell. By virtue of interacting with several transcription factors, menin is proposed to be involved in signaling pathways such as JNK, MAPK, TGF beta, and NF-κB; all of which have a well-documented role in cancer formation [60-63]. At the same time, through its role in chromatin modification, menin has been shown to affect the expression of c-Fos, hTERT, p27kip1, and p18Ink4c, which are also linked to neoplastic transformation [57,60,64,65]. On the cellular level, menin has been shown to regulate cell cycle progression and genomic integrity, both of which are often associated with a cancer phenotype.

The multiple functions of MEN1 are not altogether unconnected. As a regulator of transcription, menin could control the expression of multiple factors involved in cell cycle regulation and the DNA damage response (see the examples above). The transcription regulation is likely achieved through menin’s function in chromatin modification. At the same time, there is a wealth of evidence connecting the modification of chromatin with the maintenance of genome integrity [66]. Finally, the possibilities of MEN1’s involvement in cell cycle regulation and genome maintenance are not mutually exclusive. MEN1 was shown to regulate proper S-phase arrest in response to exogenous DNA damage [49]. Similar regulation is necessary in the cell as endogenous DNA damage occurs every cell cycle during DNA replication [67].

Taken together, the accumulated knowledge of MEN1’s potential functions and cellular partners suggests several possible mechanisms of its involvement in cancer formation. The key question is which of these functions or interactions play critical role in cancer development. One possible way to address this challenging problem is systematic investigation of tumors obtained from Men1 heterozygous mice as well as from MEN1 patients. One such study generated p18(-/-)Men1(+/-) and p27(-/-)Men1(+/-) mice and found that p18 functionally collaborates with MEN1 in suppressing lung and neuroendocrine tumors [64,65]. Another important question is whether menin aids in the maintenance of genome integrity by regulating the cell cycle or by serving as a structural component of DNA repair machinery. To this end, analysis of mutational spectra could point to a DNA repair step(s) most deficient in cells lacking MEN1. Careful examination of interactions between menin and known DNA repair proteins is also necessary. Addressing these issues is of key importance for the understanding of MEN1-related carcinogenesis and for the development of effective therapeutic approaches.

Abbreviations
MEN1Multiple endocrine neoplasia type 1

RB1Retinoblastoma

LOHLoss of heterozygosity

DEBDiepoxybutane

MEFsMouse embryonic fibroblasts

RPAReplication protein A

ESEmbryonic stem

Table 1 Familial cancer syndromes and cancer predisposition genes [8-9]
Cancer syndrome	Type of tumors	Gene(s)	Function	
Dominant mode of inheritance	
Familial retinoblastoma	Retinoblastoma, Osteosarcoma	RB	Regulator of cell proliferation	
Li-Fraumeni syndrome	Soft tissue Osteosarcoma, breast cancer, leukemia	p53, CHK2 [68]	Transcription factor, DNA damage response; Kinase, regulator of p53 activity	
Gorlin syndrome	Basal cell carcinoma	PTCH	Transmembrane receptor for hedgehog	
Familial adenomatous polyposis (FAP)	Colorectal cancer	APC	Regulation of β-catenin	
Hereditary non-polyposis colorectal cancer (HNPCC)	Colorectal cancer	MSH2, 6, MLH1, PMS1, 2	Mismatch repair	
Neurofibromatosis type 1	Neurofibromas	NF1	GAP for p21	
Neurofibromatosis type 2	Schwannomas, Meningiomas	NF2	Links membrane proteins to cytoskeleton	
Familial breast/ovarian cancer syndrome	Breast cancer, ovarian cancer	BRCA1/2	DNA repair	
von Hippel-Lindau syndrome	Renal cancer (clear cell)	VHL	Transcription elongation factor	
Hereditary papillary renal cancer (HPRC)	Renal cancer (papillary)	MET	Transmembrane receptor for HGF	
Familial melanoma	Melanoma	p16	Cyclin-dependent kinases CDK4 and CDK 6 inhibitor	
Multiple endocrine neoplasia type 1 (MEN1)	Pituitary Parathyroid adenoma, Pancreatic islet	MEN1	Transcriptional regulator, modulator of AP-1 activity	
Multiple endocrine neoplasia type 2 (MEN2)	Medullary thyroid cancer	RET	Transmembrane receptor	
Cowden disease	Breast cancer, thyroid cancer	PTEN	PI3kinase/AKT inhibitor, phosphatase	
Tuberous sclerosis	Rabdomyoma, Renal cancer	TSCI/2	Regulation of cell size and proliferation through insulin signaling	
Recessive mode of inheritance				
Bloom syndrome	Solid tumors	BLM	Helicase, DNA repair	
Ataxia telangiectasia (AT)	Lymphoma	ATM	DNA repair, DNA damage response	
Nijmegen breakage syndrome (NBS)	Lymphoma, Glioma, Medulloblastoma	NBS1	Double strand break repair	
Xeroderma pigmentosum	Skin cancer	XPB, XPD, XPA	Nucleotide excision repair	
Rothmund Thompson syndrome	Basal cell carcinoma, Squamous cell sarcoma	RECQL4	Helicase	
Werner syndrome	Oseeosarcoma, Meningioma	WRN	Helicase	
Fanconi anemia	Leukemia, Squamous cancers	FANCD2, FANCA, FANCB, C, FANCE, F, FANCG, L	DNA repair, DNA damage response	
Abbreviations: GAP - GTPase-activating protein; MSN - mut S homolog; MLH - mut L homolog; PMS - postmeiotic segregation; HGF - hepatocyte growth factor; BRCA - breast cancer associated; PTEN - phosphatase and tensin homolog.
==== Refs
Hanahan D  Weinberg RA   The hallmarks of cancer Cell 2000 100 1 57 70 10647931 
Kinzler KW  Vogelstein B   Lessons from hereditary colorectal cancer Cell 1996 87 2 159 170 8861899 
Cooper GM   Oncogenes 1995 2nd ed Sudbury, Massachusetts Jones and Bartlett Publishers 
Sherr CJ   Principles of tumor suppression Cell 2004 116 2 235 246 14744434 
Cress WD  Seto E   Histone deacetylases, transcriptional control, and cancer J Cell Physiol 2000 184 1 1 16 10825229 
Knudson AG Jr.   Mutation and cancer: statistical study of retinoblastoma Proc Natl Acad Sci USA 1971 68 4 820 823 5279523 
Friend SH  Bernards R  Rogelj S  Weinberg RA  Rapaport JM  Albert DM  Dryja TP   A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma Nature 1986 323 6089 643 646 2877398 
Garber JE  Offit K   Hereditary cancer predisposition syndromes J Clin Oncol 2005 23 2 276 292 15637391 
Fearon ER   Human cancer syndromes: clues to the origin and nature of cancer Science 1997 278 5340 1043 1050 9353177 
Mulligan LM  Eng C  Healey CS  Clayton D  Kwok JB  Gardner E    Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC Nat Genet 1994 6 1 70 74 7907913 
Schmidt L  Duh FM  Chen F  Kishida T  Glenn G  Choyke P    Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat Genet 1997 16 1 68 73 9140397 
Knudson AG   Antioncogenes and human cancer Proc Natl Acad Sci USA 1993 90 23 10914 10921 7902574 
Cannon-Albright LA  Skolnick MH   The genetics of familial breast cancer Semin Oncol 1996 23 1 2 1 5 
Lancaster JM  Wooster R  Mangion J  Phelan CM  Cochran C  Gumbs C    BRCA2 mutations in primary breast and ovarian cancers Nat Genet 1996 13 2 238 240 8640235 
Miki Y  Katagiri T  Kasumi F  Yoshimoto T  Nakamura Y   Mutation analysis in the BRCA2 gene in primary breast cancers Nat Genet 1996 13 2 245 247 8640237 
Teng DH  Bogden R  Mitchell J  Baumgard M  Bell R  Berry S    Low incidence of BRCA2 mutations in breast carcinoma and other cancers Nat Genet 1996 13 2 241 244 8640236 
Yuen ST  Chan TL  Ho JW  Chan AS  Chung LP  Lam PW    Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers Oncogene 2002 21 49 7585 7592 12386821 
Kinzler KW  Vogelstein B   Cancer-susceptibility genes. Gatekeepers and caretakers Nature 1997 386 6627 761 763 9126728 
Schussheim DH  Skarulis MC  Agarwal SK  Simonds WF  Burns AL  Spiegel AM  Marx SJ   Multiple endocrine neoplasia type 1: new clinical and basic findings Trends Endocrinol Metab 2001 12 4 173 178 11295574 
Trump D  Farren B  Wooding C  Pang JT  Besser GM  Buchanan KD    Clinical studies of multiple endocrine neoplasia type 1 (MEN1) Qjm 1996 89 9 653 669 8917740 
Agarwal SK  Lee Burns A  Sukhodolets KE  Kennedy PA  Obungu VH  Hickman AB    Molecular pathology of the MEN1 gene Ann NY Acad Sci 2004 1014 189 198 15153434 
Larsson C  Skogseid B  Oberg K  Nakamura Y  Nordenskjold M   Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma Nature 1988 332 6159 85 87 2894610 
Chandrasekharappa SC  Guru SC  Manickam P  Olufemi SE  Collins FS  Emmert-Buck MR    Positional cloning of the gene for multiple endocrine neoplasia-type 1 Science 1997 276 5311 404 407 9103196 
Lemmens I  Van de Ven WJ  Kas K  Zhang CX  Giraud S  Wautot V    Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1 Hum Mol Genet 1997 6 7 1177 1183 9215690 
Guru SC  Goldsmith PK  Burns AL  Marx SJ  Spiegel AM  Collins FS  Chandrasekharappa SC   Menin, the product of the MEN1 gene, is a nuclear protein Proc Natl Acad Sci USA 1998 95 4 1630 1634 9465067 
Bassett JH  Rashbass P  Harding B  Forbes SA  Pannett AA  Thakker RV   Studies of the murine homolog of the multiple endocrine neoplasia type 1 (MEN1) gene, men1 J Bone Miner Res 1999 14 1 3 10 
Guru SC  Crabtree JS  Brown KD  Dunn KJ  Manickam P  Prasad NB    Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene Mamm Genome 1999 10 6 592 596 10341092 
Stewart C  Parente F  Piehl F  Farnebo F  Quincey D  Silins G    Characterization of the mouse Men1 gene and its expression during development Oncogene 1998 17 19 2485 2493 9824159 
Agarwal SK  Guru SC  Heppner C  Erdos MR  Collins RM  Park SY    Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription Cell 1999 96 1 143 152 9989505 
Gallo A  Cuozzo C  Esposito I  Maggiolini M  Bonofiglio D  Vivacqua A    Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation Oncogene 2002 21 42 6434 6445 12226747 
Yumita W  Ikeo Y  Yamauchi K  Sakurai A  Hashizume K   Suppression of insulin-induced AP-1 transactivation by menin accompanies inhibition of c-Fos induction Int J Cancer 2003 103 6 738 744 12516092 
Heppner C  Bilimoria KY  Agarwal SK  Kester M  Whitty LJ  Guru SC    The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation Oncogene 2001 20 36 4917 4925 11526476 
Kaji H  Canaff L  Lebrun JJ  Goltzman D  Hendy GN   Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling Proc Natl Acad Sci USA 2001 98 7 3837 3842 11274402 
Lemmens IH  Forsberg L  Pannett AA  Meyen E  Piehl F  Turner JJ    Menin interacts directly with the homeobox-containing protein Pem Biochem Biophys Res Commun 2001 286 2 426 431 11500056 
Chandrasekharappa SC  Teh BT   Functional studies of the MEN1 gene J Intern Med 2003 253 6 606 615 12755956 
La P  Silva AC  Hou Z  Wang H  Schnepp RW  Yan N    Direct binding of DNA by tumor suppressor menin J Biol Chem 2004 279 47 49045 49054 15331604 
Kim H  Lee JE  Cho EJ  Liu JO  Youn HD   Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex Cancer Res 2003 63 19 6135 6139 14559791 
Yokoyama A  Wang Z  Wysocka J  Sanyal M  Aufiero DJ  Kitabayashi I    Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression Mol Cell Biol 2004 24 13 5639 5649 15199122 
Hughes CM  Rozenblatt-Rosen O  Milne TA  Copeland TD  Levine SS  Lee JC    Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus Mol Cell 2004 13 4 587 597 14992727 
Milne TA  Hughes CM  Lloyd R  Yang Z  Rozenblatt-Rosen O  Dou Y    Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors Proc Natl Acad Sci USA 2005 102 3 749 754 15640349 
Yokoyama A  Somervaille TC  Smith KS  Rozenblatt-Rosen O  Meyerson M  Cleary ML   The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis Cell 2005 123 2 207 218 16239140 
Scacheri PC  Davis S  Odom DT  Crawford GE  Perkins S  Halawi MJ    Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis PLoS Genet 2006 2 4 e51 16604156 
Agarwal SK  Impey S  McWeeney S  Scacheri PC  Collins FS  Goodman RH    Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation Neoplasia 2007 9 2 101 107 17356705 
Itakura Y  Sakurai A  Katai M  Ikeo Y  Hashizume K   Enhanced sensitivity to alkylating agent in lymphocytes from patients with multiple endocrine neoplasia type 1 Biomed Pharmacother 2000 54 1 187s 190s 10915021 
Jin S  Mao H  Schnepp RW  Sykes SM  Silva AC  D'Andrea AD  Hua X   Menin associates with FANCD2, a protein involved in repair of DNA damage Cancer Res 2003 63 14 4204 4210 12874027 
Sukhodolets KE  Hickman AB  Agarwal SK  Sukhodolets MV  Obungu VH  Novotny EA    The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene Mol Cell Biol 2003 23 2 493 509 12509449 
Binz SK  Sheehan AM  Wold MS   Replication protein A phosphorylation and the cellular response to DNA damage DNA Repair (Amst) 2004 3 8-9 1015 1024 15279788 
Busygina V  Suphapeetiporn K  Marek LR  Stowers RS  Xu T  Bale AE   Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1 Hum Mol Genet 2004 13 20 2399 2408 15333582 
Busygina V  Kottemann MC  Scott KL  Plon SE  Bale AE   Multiple Endocrine Neoplasia Type 1 Interacts with Forkhead Transcription Factor CHES1 in DNA Damage Response Cancer Res 2006 66 17 8397 8403 16951149 
Kim YS  Burns AL  Goldsmith PK  Heppner C  Park SY  Chandrasekharappa SC    Stable overexpression of MEN1 suppresses tumorigenicity of RAS Oncogene 1999 18 43 5936 5942 10557080 
Bertolino P  Radovanovic I  Casse H  Aguzzi A  Wang ZQ  Zhang CX   Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs Mech Dev 2003 120 5 549 560 12782272 
Schnepp RW  Hou Z  Wang H  Petersen C  Silva A  Masai H  Hua X   Functional interaction between tumor suppressor menin and activator of S-phase kinase Cancer Res 2004 64 18 6791 6796 15374998 
Biondi CA  Gartside MG  Waring P  Loffler KA  Stark MS  Magnuson MA    Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues Mol Cell Biol 2004 24 8 3125 3131 15060136 
Crabtree JS  Scacheri PC  Ward JM  Garrett-Beal L  Emmert-Buck MR  Edgemon KA    A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors Proc Natl Acad Sci USA 2001 98 3 1118 1123 11158604 
Crabtree JS  Scacheri PC  Ward JM  McNally SR  Swain GP  Montagna C    Of mice and MEN1: Insulinomas in a conditional mouse knockout Mol Cell Biol 2003 23 17 6075 6085 12917331 
Suphapeetiporn K  Greally JM  Walpita D  Ashley T  Bale AE   MEN1 tumor-suppressor protein localizes to telomeres during meiosis Genes Chromosomes Cancer 2002 35 1 81 85 12203793 
Lin SY  Elledge SJ   Multiple tumor suppressor pathways negatively regulate telomerase Cell 2003 113 7 881 889 12837246 
Lopez-Egido J  Cunningham J  Berg M  Oberg K  Bongcam-Rudloff E  Gobl A   Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity Exp Cell Res 2002 278 2 175 183 12169273 
Obungu VH  Lee Burns A  Agarwal SK  Chandrasekharapa SC  Adelstein RS  Marx SJ   Menin, a tumor suppressor, associates with nonmuscle myosin II-A heavy chain Oncogene 2003 22 41 6347 6358 14508515 
Heasley LE  Han SY   JNK regulation of oncogenesis Mol Cells 2006 21 2 167 173 16682809 
Zebisch A  Czernilofsky AP  Keri G  Smigelskaite J  Sill H  Troppmair J   Signaling through RAS-RAF-MEK-ERK: from basics to bedside Curr Med Chem 2007 14 5 601 623 17346150 
Matsuzaki K  Okazaki K   Transforming growth factor-beta during carcinogenesis: the shift from epithelial to mesenchymal signaling J Gastroenterol 2006 41 4 295 303 16741607 
Karin M  Greten FR   NF-kappaB: linking inflammation and immunity to cancer development and progression Nat Rev Immunol 2005 5 10 749 759 16175180 
Pei XH  Bai F  Smith MD  Xiong Y   p18Ink4c Collaborates with Men1 to Constrain Lung Stem Cell Expansion and Suppress Non-Small-Cell Lung Cancers Cancer Res 2007 67 7 3162 3170 17409423 
Bai F  Pei XH  Nishikawa T  Smith MD  Xiong Y   p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors Mol Cell Biol 2007 27 4 1495 1504 17145768 
Morrison AJ  Shen X   Chromatin modifications in DNA repair Results Probl Cell Differ 2006 41 109 125 16909893 
Sung P  Klein H   Mechanism of homologous recombination: mediators and helicases take on regulatory functions Nat Rev Mol Cell Biol 2006 7 10 739 750 16926856 
Staalesen V  Falck J  Geisler S  Bartkova J  Borresen-Dale AL  Lukas J    Alternative splicing and mutation status of CHEK2 in stage III breast cancer Oncogene 2004 23 52 8535 8544 15361853

